RT Journal Article
SR Electronic
T1 Monitoring of Serum Her-2/<em>neu</em> Predicts Histopathological Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1127
OP 1130
VO 24
IS 2C
A1 KÖSTLER, WOLFGANG J.
A1 STEGER, GÜNTHER G.
A1 OLEIMAN, AFSCHIN
A1 SCHWAB, BARBARA
A1 SINGER, CHRISTIAN F.
A1 TOMEK, SANDRA
A1 BRODOWICZ, THOMAS
A1 KRAINER, MICHAEL
A1 WILTSCHKE, CHRISTOPH
A1 HORVAT, REINHARD
A1 JAKESZ, RAIMUND
A1 ZIELINSKI, CHRISTOPH C.
YR 2004
UL http://ar.iiarjournals.org/content/24/2C/1127.abstract
AB Background: This prospective pilot study was performed to elucidate whether early changes in serum levels of the Her-2/neu extracellular domain (ECD) reflect histopathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing breast cancer. Patients and Methods: ECD levels were measured throughout neoadjuvant trastuzumab-based treatment in 16 patients using a Her-2/neu Microtiter ELISA. Results: In 9 (56%) patients with Her-2/neu shedding tumors (ECD &gt;15ng/ml), ECD values (in % of baseline) of non-responders vs. responders were 117% vs. 55% on day 8 (p=0.014), 157% vs. 58% on day 22 (p=0.061) and 114% vs. 46% at restaging (p=0.049). Conclusion: Serial monitoring of serum Her-2/neu ECD levels may represent a valuable tool to predict pathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing tumors. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved